Palbociclib plus fulvestrant as second- or later-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase 2 study. 30. September 2019 Lüftner D, Welslau M, Liersch R, Deryal M, Brucker C, Rauh J, Welt A, Zaiss M, Sahlmann J, Houet L, Vannier C, Potthoff K, Marschner N, 2019. Ann Oncol, Volume 30, v135 Advanced renal cell carcinoma: first results from the prospective research platform CARAT for patients with mRCC in Germany. Goebell PJ, Müller L, Grüllich C, Reichert D, Bögemann M, Dörfel S, von der Heyde E, Binninger A, Jänicke M, Marschner N, Staehler M, Grünwald… Weiterlesen Patients with metastatic non-small cell lung cancer and targetable molecular alterations in Germany. Treatment and first outcome data from the prospective German Registry Platform CRISP (AIO-TRK-0315). Griesinger F, Eberhardt WEE, Nusch A, Reiser M, Zahn MO, Marschner N, Jaenicke M, Fleitz A, Spring L, Sahlmann J, Karatas A, Hipper A, Weichert… Weiterlesen